333 related articles for article (PubMed ID: 33115610)
1. Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response.
Wilson DM; Deacon AM; Duncton MAJ; Pellicena P; Georgiadis MM; Yeh AP; Arvai AS; Moiani D; Tainer JA; Das D
Prog Biophys Mol Biol; 2021 Aug; 163():130-142. PubMed ID: 33115610
[TBL] [Abstract][Full Text] [Related]
2. A New Drug Discovery Platform: Application to DNA Polymerase Eta and Apurinic/Apyrimidinic Endonuclease 1.
Das D; Duncton MAJ; Georgiadis TM; Pellicena P; Clark J; Sobol RW; Georgiadis MM; King-Underwood J; Jobes DV; Chang C; Gao Y; Deacon AM; Wilson DM
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068959
[TBL] [Abstract][Full Text] [Related]
3. The cutting edges in DNA repair, licensing, and fidelity: DNA and RNA repair nucleases sculpt DNA to measure twice, cut once.
Tsutakawa SE; Lafrance-Vanasse J; Tainer JA
DNA Repair (Amst); 2014 Jul; 19():95-107. PubMed ID: 24754999
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
Li Q; Kang C
Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
[TBL] [Abstract][Full Text] [Related]
5. Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH).
Wilson DM; Duncton MAJ; Chang C; Lee Luo C; Georgiadis TM; Pellicena P; Deacon AM; Gao Y; Das D
Front Oncol; 2021; 11():778925. PubMed ID: 34900730
[TBL] [Abstract][Full Text] [Related]
6. Novel approach of fragment-based lead discovery applied to renin inhibitors.
Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
[TBL] [Abstract][Full Text] [Related]
7. Fragment-Based Drug Discovery against Mycobacteria: The Success and Challenges.
Togre NS; Vargas AM; Bhargavi G; Mallakuntla MK; Tiwari S
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142582
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.
Coutard B; Decroly E; Li C; Sharff A; Lescar J; Bricogne G; Barral K
Antiviral Res; 2014 Jun; 106():61-70. PubMed ID: 24704437
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes.
Ward TA; McHugh PJ; Durant ST
PLoS One; 2017; 12(6):e0179278. PubMed ID: 28628639
[TBL] [Abstract][Full Text] [Related]
10. Structure-based virtual screening toward the discovery of novel inhibitors of the DNA repair activity of the human apurinic/apyrimidinic endonuclease 1.
Guerreiro PS; Estácio SG; Antunes F; Fernandes AS; Pinheiro PF; Costa JG; Castro M; Miranda JP; Guedes RC; Oliveira NG
Chem Biol Drug Des; 2016 Dec; 88(6):915-925. PubMed ID: 27450574
[TBL] [Abstract][Full Text] [Related]
11. Counting on Fragment Based Drug Design Approach for Drug Discovery.
Kashyap A; Singh PK; Silakari O
Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
[TBL] [Abstract][Full Text] [Related]
12. Targeting the DNA damage response in oncology: past, present and future perspectives.
Basu B; Yap TA; Molife LR; de Bono JS
Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
[TBL] [Abstract][Full Text] [Related]
13. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
[TBL] [Abstract][Full Text] [Related]
14. Diverse small molecule inhibitors of human apurinic/apyrimidinic endonuclease APE1 identified from a screen of a large public collection.
Dorjsuren D; Kim D; Vyjayanti VN; Maloney DJ; Jadhav A; Wilson DM; Simeonov A
PLoS One; 2012; 7(10):e47974. PubMed ID: 23110144
[TBL] [Abstract][Full Text] [Related]
15. From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery.
Ferreira LG; Andricopulo AD
Curr Top Med Chem; 2017; 17(20):2260-2270. PubMed ID: 28240184
[TBL] [Abstract][Full Text] [Related]
16. Fragments: where are we now?
Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors.
Zawahir Z; Dayam R; Deng J; Pereira C; Neamati N
J Med Chem; 2009 Jan; 52(1):20-32. PubMed ID: 19072053
[TBL] [Abstract][Full Text] [Related]
18. Library Design Strategies To Accelerate Fragment-Based Drug Discovery.
Troelsen NS; Clausen MH
Chemistry; 2020 Sep; 26(50):11391-11403. PubMed ID: 32339336
[TBL] [Abstract][Full Text] [Related]
19. The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery.
Bradley AR; Echalier A; Fairhead M; Strain-Damerell C; Brennan P; Bullock AN; Burgess-Brown NA; Carpenter EP; Gileadi O; Marsden BD; Lee WH; Yue W; Bountra C; von Delft F
Essays Biochem; 2017 Nov; 61(5):495-503. PubMed ID: 29118096
[TBL] [Abstract][Full Text] [Related]
20. Crystallographic fragment screening in academic cancer drug discovery.
Martin MP; Endicott JA; Noble MEM; Tatum NJ
Methods Enzymol; 2023; 690():211-234. PubMed ID: 37858530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
